Opinion: Trump’s executive order on psychedelics is the right move. But is my field ready for it?

President Trump signed an executive order on psychedelic medicines to accelerate approval timelines and expand research. The order directs the Food and Drug Administration to issue priority review vouchers and dedicates $50 million in ARPA-H funding to psychedelic research. The move aims to develop novel treatments for mental health conditions.